Pathophysiology of neuronal energy crisis in Alzheimer's disease

Neurodegenerative Diseases

Volumn 5, Issue 3-4, 2008, Pages 126-132

  De La Torre, Jack C ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Aging; Alzheimer's disease; Brain hypoperfusion; Critically attained threshold of cerebral hypoperfusion; Neuroimaging; Neuronal energy metabolism; Vascular risk factors

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; PROTEIN; REACTIVE OXYGEN METABOLITE; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; BRAIN ATROPHY; BRAIN BLOOD FLOW; BRAIN METABOLISM; BRAIN PERFUSION; COGNITIVE DEFECT; CONFERENCE PAPER; DEMENTIA; ENERGY METABOLISM; HEART DISEASE; HIPPOCAMPUS; HUMAN; ION TRANSPORT; MEMORY DISORDER; MICROTUBULE; NERVE FIBER; NEUROIMAGING; NEUROTRANSMISSION; OXIDATIVE STRESS; PARIETAL LOBE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RISK FACTOR; SIGNAL TRANSDUCTION; STROKE;

ALZHEIMER DISEASE; ANIMALS; BRAIN; ENERGY METABOLISM; HUMANS; NEURONS;

EID: 40449117446     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000113681     Document Type: Conference Paper

References (39)

1. de la Torre JC: Impact of heart disease and stroke on Alzheimer's disease. Neurol Res 2006;28:577-679.
2. de la Torre JC, Fortin T, Park G, Butler K, Kozlowski P, Pappas, B, de Socarraz H, Saunders JF, Richard M: Chronic cerebrovascular insufficiency induces dementia-like deficits in aged rats. Brain Res 1992;582:186-195.
3. de la Torre JC, Fortin T, Saunders J: Correlates between NMR spectroscopy, diffusion weighted imaging and CA1 morphometry following chronic brain ischemia. J Neurosci Res 1995;41:238-245.
4. de la Torre JC, Mussivand T: Can disturbed brain microcirculation cause Alzheimer's disease? Neurol Res 1993;15:146-153.
5. Breteler MM: Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 2000;21:153-160.
6. Aguero-Torres H, Kivipelto M, von Strauss E: Rethinking the dementia diagnoses in a population-based study: what is Alzheimer's disease and what is vascular dementia? A study from the Kungsholmen project. Dement Geriatr Cogn Disord 2006;22:244-249.
7. Alves TC, Busatto GF: Regional cerebral blood flow reductions, heart failure and Alzheimer's disease. Neurol Res 2006;28:579-587.
8. Miklossy J: Cerebral hypoperfusion induces cortical watershed microinfarcts which may further aggravate cognitive decline in Alzheimer's disease. Neurol Res 2003;25:605-610.
9. Korf ES, Scheltens P, Barkhof F, de Leeuw FE: Blood pressure, white matter lesions and medial temporal lobe atrophy: closing the gap between vascular pathology and Alzheimer's disease? Dement Geriatr Cogn Disord 2005;20:331-337.
10. Johnson KA, Jones K, Holman BL, Becker J, Spiers PA, Satlin A, Albert MS: Preclinical prediction of Alzheimer's disease using SPECT. Neurology 1998;50:1563-1571.
11. Ruitenberg A, den Heiker T, Bakker SL: Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam study. Ann Neurol 2005;57:789-794.
12. de la Torre JC: Alzheimer's disease is a vasocognopathy: a new term to describe its nature. Neurol Res 2004;26:517-524.
13. Elias MF, Wolf PA, D'Agostino RB, Cobb J, White LR: Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol 1993;138:353-364.
14. Ivan CS, Seshadri S, Beiser A: Dementia after stroke: the Framingham Study. Stroke 2004;35:1264-1268.
15. de la Torre JC: Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer's pathogenesis. Neurobiol Aging 2000;903:424-436.
16. Leenders KL, Perani D, Lammertsma AA, Heather JD, Buckingham P, Healy MJ, Gibbs JM, Wise RJ, Hatazawa J, Herold S: Cerebral blood flow, blood volume and oxygen utilization. Normal values and effect of age. Brain 1990;113:27-47.
17. Velliquette RA, O'Connor T, Vassar R: Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J Neurosci 2005;25:10874-10883.
18. de la Torre JC, Kalaria RN, Nakajima K, Nagata K: Alzheimer's disease: vascular epidemiology and pathology. Ann NY Acad Sci 2002;977:1-535.
19. Cacabelos R, Fernandez-Novoa L, Lombardi V, Kubota Y, Takeda M: Molecular genetics of Alzheimer's disease and aging. Methods Find Exp Clin Pharmacol 2005;27(suppl A):1-573.
20. de la Torre JC: Alzheimer's disease as a vascular disorder: nosological evidence. Stroke 2002;33:1152-1162.
21. de la Torre JC: Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma and dialectics. Lancet Neurol 2004;3:184-190.
22. Hayden KM, Zandi PP, Lyketsos CG, Khachaturian AS, Bastian LA, Charoonruk G, Tschanz JT, Norton MC, Pieper CF, Munger RG, Breitner JC, Welsh-Bohmer KA: Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis Assoc Disord 2006;20:93-100.
23. Sjogren M, Mielke M, Gustafson D, Zandi P, Skoog I: Cholesterol and Alzheimer's disease - Is there a relation? Mech Ageing Dev 2006;127:138-147.
24. Wolozin B, Kellman W, Ruosseau P, Celesia G, Siegel G: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-1443.
25. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA, Breitner JC; Cache County Study investigators: Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 2005;62:217-224.
26. Laufs U, La Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135.
27. Endres M, Laufs U, Huang Z: Stroke protection by 3-hydroxy-3- methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998;95:8880-8885.
28. Maxwell AJ: Mechanisms of dysfunction of the nitric oxide pathway in vascular diseases. Nitric Oxide 2002;6:101-124.
29. Grundy SM, Cleeman JI, Daniels SR, Donato KA: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752.
30. Vanhanen M, Koivisto K, Moilanen L, Helkala EL, Hanninen T, Soininen H, Kervinen K, Kesaniemi YA, Laakso M, Kuusisto J: Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 2006;67:843-847.
31. Martins IJ, Hone E, Foster JK, Sunram-Lea SI, Gnjec A, Fuller SJ, Nolan D, Gandy SE, Martins RN: Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 2006;11:721-736.
32. Desmond DW, Moroney JT, Sano M, Stern Y: Incidence of dementia after ischemic stroke: results of a longitudinal study. Stroke 2002;33:2261-2262.
33. Tatemichi TK, Paik M, Bagiella E, Desmond DW, Stern Y: Risk of dementia after stroke in a hospitalized cohort: results of a longitudinal study. Neurology 1994;44:1885-1891.
34. Brown WD, Frackowiak RSJ: Cerebral blood flow and metabolism studies in multi-infarct dementia. Alzheimer Dis Assoc Disord 1991;5:131-143.
35. de Leon MJ, Mosconi L, Blennow K, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Tsui W, Saint Louis LA, Sobanska L, Brys M, Li Y, Rich K: Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann NY Acad Sci 2007;1097:114-145.
36. Mosconi L, De Santi S, Li J, Tsui WH, Li Y, Boppana M, Laska E, Rusinek H, de Leon MJ: Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging, in press.
37. Gebremedhin D, Lange AR, Lowry TF, Taheri MR, Birks EK, Hudetz AG, Narayanan J, Falck JR, Okamoto H, Roman RJ, Nithipatikom K, Campbell WB, Harder DR: Production of 20-HETE and its role in autoregulation of cerebral blood flow. Circ Res 2000;87:60-65.
38. Johnson NA, Jahng GH, Weiner MW, Miller BL, Chui HC, Jagust WJ, Gorno-Tempini ML, Schuff N: Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 2005;234:851-859.
39. Silverman DH, Phelps ME: Application of positron emission tomography for evaluation of metabolism and blood flow in human brain: normal development, aging, dementia, and stroke. Mol Genet Metab 2001;74:128-138.